Across TCGA pan-cancer cohorts, BRI3BPP1 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of BRI3BPP1’s most consistent transcriptional readouts.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where BRI3BPP1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types BRI3BPP1 is over-expressed in tumor, although a few such as LUSC show the opposite, repressed pattern.
KIRC, BRCA, and LUSC are the cancer types where BRI3BPP1 tumor–normal differential expression is most reproducible.